NEW YORK, July 11, 2016 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Sagent Pharmaceuticals, Inc. ("Sagent" or the "Company") (NASDAQ: SGNT) concerning the proposed acquisition of the Company by Nichi-Iko Pharmaceutical Co., Ltd. ("Nichi-Iko").
Under the terms of the offer, Sagent would acquire Nichi-Iko in a transaction valued at approximately $736 million. Pursuant to the deal, Sagent stockholders will be offered $21.75 per share in cash. At least one Wall Street analyst has set a target price of $25 per share for Sagent stock.
Our investigation concerns whether the Sagent board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company stockholders.
If you own Sagent shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Benjamin I. Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-sagent-pharmaceuticals-inc-300296786.html
SOURCE Harwood Feffer LLP